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Lambert-Eaton Myasthenic Syndrome (LEMS) is a rare disease with a well-characterized pathogenesis. In 50% of the patients,
LEMS is a paraneoplastic manifestation and caused by a small cell lung carcinoma (SCLC). Both LEMS patients with SCLC
and those without this tumour have in 85% of cases pathogenetic antibodies of very high LEMS speciﬁcity against voltage-
gated calcium channels (VGCCs) in the cell membrane of the presynaptic motor nerve terminal. Better understanding of LEMS
pathogenesis has lead to targeted symptomatic therapy aimed at the neuromuscular junction and to semispeciﬁc immuno-
suppression. For SCLC LEMS, tumour therapy is essential.
1.Introduction
The neuromuscular synapse represents a predilection site for
disease. Autoimmune, genetic, and toxic disorders are linked
to the neuromuscular junction. The dominating symptom
of all such disorders is muscular weakness. The disorders
interferewiththeacetylcholine-mediatedtransmissionofthe
signalfromthepresynapticnervetoskeletalmuscles,impair-
ing muscle contraction. Both the autoimmune, genetic and
toxic conditions can eﬀect either pre- or postsynaptically.
Mutated genes leading to a change in protein function result
in myasthenic syndromes of various types, the postsynaptic
acetylcholine receptor most often the target, or also proteins
in the postsynaptic membrane functionally linked to this
receptor. Toxins exert their function pre- or postsynaptically
and will paralyze either attacker or prey in nature’s ﬁght
for survival. Such toxins are widely used in medicine, both
therapeutically and for diagnostic and research purposes.
Lambert-Eaton Myasthenic Syndrome (LEMS) repre-
sents one of the distinct autoimmune disorders at the neuro-
muscularjunction.In1956,Lambertandcoworkersreported
6 patients with atypical myasthenia, lung carcinoma, and
a speciﬁc response to repeated nerve stimulation diﬀering
from myasthenia gravis [1]. During recent years, disease
mechanisms have been thoroughly elucidated for LEMS, so
thatthisdisordercannowbecharacterizedasamodeldisease
forotherautoimmuneandparaneoplasticdisorders.LEMSis
caused by pathogenic autoantibodies to presynaptic voltage-
gated calcium channels (VGCCs) in the membrane of the
motor nerve terminal, impairing acetylcholine release, and
therebycausingdistinctweaknessofstriatedskeletalmuscles.
The challenge now is to transfer this detailed pathogenetic
knowledge into even more eﬀective therapy.
2. Epidemiology
LEMS fulﬁls the criteria for a rare disease. In a study from
South Holland, Wirtz et al. [2]f o u n daL E M Sp r e v a l e n c e
of 2.3 per million and an annual incidence rate of 0.5 per
million. This incidence was 1.4 times lower than what they
found for myasthenia gravis. A low prevalence relative to
incidence reﬂects the poor survival of LEMS patients with
the paraneoplastic type of disease. 60% of the LEMS patients
were males. Mean age of debut was 58 years. There seems to
be two peaks for age of onset, one around 40 years and one
at a higher age, similar to what is seen for myasthenia gravis
[3].
LEMS is subclassiﬁed into two main subgroups; LEMS
combinedwithsmallcelllungcarcinoma(SCLC),andLEMS2 Autoimmune Diseases
with no SCLC. The no-SCLC LEMS group is dominating
regardingprevalenceasthisgrouphasanearnormalsurvival
rate. No-SCLC LEMS patients have a lower age of debut
t h a nS C L CL E M S[ 3, 4]. LEMS with SCLC shows a male
preponderance, reﬂecting smoking habits. The frequency of
LEMS among the total SCLC patient population is reported
between 0.5 and 3% [2, 5]. LEMS-related autoantibodies
occur in a higher proportion of SCLC patients, but without
leading to manifest neuromuscular disease. SCLC patients
withLEMStend to be youngerthan thosewithoutLEMS[6].
3.ClinicalPicture
Muscle weakness represents the hallmark of LEMS. This
weakness starts nearly always in proximal muscle groups,
especially in the legs. 80% of LEMS patients experience
proximal weakness in both arms and legs [4, 7, 8]. Also
facial weakness, eye muscle complaints, bulbar muscular
weakness, and distal pareses are relatively common. LEMS
with SCLC tends to have more severe muscle weakness and
with a distinct progression. Areﬂexia is a common ﬁnding.
Autonomicdysfunctionisthesecondtypicalsymptomof
LEMS. Such symptoms are milder and have less functional
signiﬁcance than muscular weakness. However, it aﬀects
a large majority of LEMS patients. Dry mouth, dry eyes,
erectile dysfunction, constipation and reduced sweating are
frequently conﬁrmed when examining LEMS patients, and
to the same degree for patients with and without SCLC.
4. Pathogenesis
LEMS is caused by autoantibodies to VGCC in the presy-
naptic neuronal cell membrane. Such antibodies show a
high sensitivity, as they can be detected in 85% of all
LEMSpatients.TheLEMSspeciﬁcityinpatientswithdistinct
muscle weakness is nearly 100%. Among SCLC patients
without any symptoms of muscle weakness or autonomic
dysfunction,3–5% haveVGCC antibodies. VCCC antibodies
are hardly ever found in other control groups, but have been
described in patients with clinically pure cerebellar ataxia.
Thepresynapticreleaseofacetylcholineisacomplexpro-
cess. The VGCC antibodies in LEMS lead to a reduction in
thequantalreleaseofacetylcholine[9].Adirectpathogenetic
eﬀect of the autoantibodies has been shown by injection in
experimental animals and supported by the patients’ clinical
and electrophysiological response to plasma exchange with
removal of the autoantibodies. The number of VGCC is
reduced in LEMS patients, caused by antibody-mediated
cross-linking of the ionic channels. Research groups in
Oxford and at the Mayo Clinic have been very active in
elucidating these disease mechanisms.
The autonomic dysfunction in LEMS is probably caused
by the same VGCC antibodies that cause the muscle
weakness. The antibodies impair transmitter release from
parasympathetic and sympathetic neurons through down-
regulation of the receptors [10, 11].
VGCC mediates calcium inﬂux into the nerve termi-
nal. This inﬂux activates presynaptic signalling pathways.
Synaptotagmin, synaptobrevin, synthaxin, and SNAP-25
are molecules taking part in the interaction between the
increased intracellular calcium concentration and the release
of acetylcholine from preformed synaptic vesicles. With
calcium inﬂux being hampered by the VGCC antibodies,
presynaptic compensatory mechanisms inﬂuence acetyl-
choline release. This complex interaction has recently been
reviewed by Takamori [11]. Non-VGCC molecules inﬂuenc-
ing presynaptic acetylcholine release have been examined
as potential targets for autoantibodies in LEMS patients
without VGCC antibodies. By a similar approach, MuSK
was identiﬁed as an alternative antigen target in myasthenia
gravis. For LEMS, alternative antigens have been suggested
but not ﬁnally proven
VGCC represents multisubunit ionic channels, and com-
prising 4 or 5 subunits. Membrane depolarisation opens
the central pore for calcium inﬂux. Electrical signals are
thereby coupled to neurotransmission, secretion, and other
events in various cell types. Nonvoltage-gated calcium
channels respond to other types of stimuli, for example
mechanical stretch. The role of VGCC for neuromuscu-
lar synaptic transmission and disease was recently nicely
reviewed by Urbano et al. [12], that review concentrating on
the molecular processes related to VGCC subtypes. VGCC
were initially grouped according to tissue where they were
detected, and/or their pharmacological properties; L, P/Q,
N, K, T. The LEMS autoantibodies are directed selectively
against the P/Q subtype of VGCC. More recently VGCC
has been grouped in an alternative way according to the
gene name of their alpha 1 subunit, which also reﬂects
their protein structure. VGCC properties have now been
examined in detail and linked to molecular sequence. The
VGCC recognized by the autoantibodies in LEMS are of the
Cav 2.1 subtype, both at the motor and autonomic axon
terminals. The antibodies may to some degree bind also to
other VGCC subtypes, especially to Cav 2.2 [13]. However,
the primary target and the cause of the down-regulation is
bindingtoCav 2.1[12,14].AlthoughVGCCdownregulation
represents the main mechanism for dysfunction, also a direct
antibody-mediated channel block has been reported. Most
VGCC antibodies in LEMS are directed against the alpha-
1 subunit. The exact pattern of epitope reactivity seems
to diﬀer between LEMS patients with and without SCLC
[15].
The role of T lymphocytes has not been established
in LEMS. T cells do not aggregate around the presynaptic
terminal. In contrast to myasthenia gravis, no morphological
or functional disturbances have been reported in thymus or
other lymphoid organs. However, the expression of T cell
markers in LEMS patients suggested a down-regulation of
immunosuppressioninSCLCpatientswithLEMS,compared
to such patients without LEMS [16]. T cell immunoregula-
tion may therefore facilitate or counteract the development
of LEMS. T cell activity in the SCLC tissue may be relevant
for the induction of LEMS.
A genetic susceptibility has been established for nearly all
autoimmune disorders, both from family history and from
susceptibility genes, especially HLA-antigens. LEMS without
SCLC is signiﬁcantly associated with HLA-B8 (HLA- class I),Autoimmune Diseases 3
and HLA -DR3 and -DQ2 (HLA-class II) [3, 17]. About two-
thirds of nontumour LEMS patients compared to one-third
of controls have this HLA-pattern. This is not surprising, as
the same HLA genotypes are found with increased frequency
in most autoimmune disorders, including myasthenia gravis.
The clinically well-known autoimmune overlap manifests
through this joint genotype. A unique observation is the
report of monozygous twins, one with LEMS and VGCC
antibodies, the other with myasthenia gravis and acetyl-
choline receptor antibodies [18].
In contrast, no relation has been found for SCLC
LEMS and HLA [3]. This indicates a pathogenetic diﬀerence
between the two LEMS subtypes. The same observation
is true for myasthenia gravis, where there is no HLA-
association for the paraneoplastic, thymoma-associated sub-
type. Nor do paraneoplastic disorders in general show a con-
sistent HLA-pattern. Patients with paraneoplastic disorders
do not have an increased frequency of the HLA-genotypes
that are associated with nonparaneoplastic autoimmunity.
Tumour tissue from SCLC LEMS patients expresses a
reduced amount of HLA class I antigens compared to tissue
from SCLC patients without LEMS [19].
For the 50% of LEMS patients with a SCLC, the tumour
representstheinitiatingLEMSevent.VGCCareexpressedon
the surface of the SCLC cells [20]. This expression of cancer-
related neoantigens induces the autoantibody production,
and the autoantibodies cross-react with presynaptic VGCC
antigens.Thisinductionofautoimmunityusuallytakesplace
earlyintumourdevelopment,inmostpatientsbeforeaSCLC
diagnosis has been established, and before even a malignant
or lung disease has been suspected.
In the remaining LEMS patients, that is, those with no
SCLC, no initiating event can be identiﬁed. Such patients
do not develop a SCLC or any another malignant or lung
disorder later, linked to their LEMS. This is again similar to
other autoimmune disorders. Cross-reactivity of antibodies
occurring as a response to a clinical or subclinical infection
would have been a plausible explanation, but has been
impossible to conﬁrm.
Antibodies against SOX proteins (sry-like high-mobility
group box) represent a speciﬁc serological marker for SCLC
[6]. No pathogenetic role has been established for the SOX
antibodies. However, they occur more frequently in SCLC
LEMS (67%) than in SCLC no-LEMS (36%).
5.Diagnosis
The LEMS diagnosis is suspected from typical clinical
symptoms; the triad of muscle weakness with a typical
distribution, areﬂexia, and autonomic dysfunction. Presence
of VGCC autoantibodies conﬁrms the LEMS diagnosis, due
to the very high antibody speciﬁcity. Absence of detectable
VGCC antibodies does not rule out LEMS. Neurophysio-
logical tests with adequate repetitive stimulation undertaken
in relevant muscles strongly support a diagnosis of LEMS.
Therapeuticresponsetodrugsincreasingacetylcholine avail-
ability at the postsynaptic receptor is expected, but has no
strong diagnostic value, less than for myasthenia gravis.
The most frequent misdiagnosis is probably seronegative
and atypical myasthenia gravis or unspeciﬁed myasthenic
syndromes.
Once a diagnosis of LEMS has been conﬁrmed, or even
suspected, starts the search for a SCLC. Smoking markedly
increases this risk, but nonsmokers should undergo the same
diagnostic program. Extensive imaging is necessary, and if
necessary including PET. If the initial search is negative, the
screening should be repeated after 3 months, and then every
6 months up till 2 years after LEMS debut, this according
to recent EFNS guidelines [21]. SOX antibodies represent
an additional marker of diagnostic value in LEMS patients,
as they have high speciﬁcity for SCLC, although lower
sensitivity [6]. Two national cohorts (Dutch and English)
with a total of 219 patients were recently used to develop
a clinical score for predicting SCLC in LEMS [22]. Age
at onset, smoking, weight loss, general well-being, bulbar
involvement, male sexual impotence, and SOX antibodies
were all independent predictors for SCLC in LEMS.
6.AssociatedDisease
The most important disease association is the one between
LEMS and SCLC. One half of LEMS patients have a
paraneoplastic disorder. Other tumours do probably not
occur with any increased frequency in LEMS. Whereas SCLC
canbelinkedtovariousparaneoplasticdisordersandvarious
autoantibodies, LEMS is linked to a SCLC only.
LEMS patients with no SCLC have an increased occur-
rence of other autoimmune disorders, at least in part due to
a genetic predisposition for autoimmune reactivity.
An increasing number of rare disorders of the central
nervous system have been found to be associated with serum
autoantibodies to ion channels, receptors, or associated
proteins in the cell membrane. Some of these autoantibodies
are also pathogenic. Encephalitis can be caused by antibodies
tovoltage-gatedpotassiumchannels(VGKC)andtoNMDA-
receptors, and antibodies to GAD and aquaporin 4 are
associated with distinct neurological syndromes. VGCC
antibodies and LEMS can also coexist with central nervous
system disease. Among SCLC patients diagnosed with para-
neoplasticsubacutecerebellardegeneration,16%werefound
with concomitant LEMS, and 24% with increased VGCC
antibody levels [23, 24]. Cerebellar ataxia has been reported
also in a few nonparaneoplastic LEMS patients with VGCC
antibodies [25].
7. Therapeutic Principles
LEMS pathogenesis points directly to potential treatment
principles. The reduced quantal content release of acetyl-
cholinecanbecounteractedbysymptomatictherapy.Acetyl-
choline esterase inhibition will increase the amount of
acetylcholine in the synaptic cleft. Therapy with pyridostig-
mine and similar inhibitors has usually a positive eﬀect,
but less so and less predictably than in myasthenia gravis.
Acetylcholine esterase inhibition should be tried, but is
perhaps not ﬁrst-line therapy [26, 27]. 3,4 diaminopyridine4 Autoimmune Diseases
is an aminopyridine that blocks presynaptic voltage-gated
potassium channels and thereby prolongs the duration of
the presynaptic action potential. The amount of acetyl-
choline released increases. The positive clinical eﬀect of
3,4 diaminopyridine is well documented [26, 28]. The 3,4
diaminopyridine phosphate salt has recently been marketed
[9].
IfsymptomaticLEMStreatmentisinsuﬃcient,immuno-
suppressive drug therapy should be initiated. A combination
of prednisone/prednisolone and azathioprine is best docu-
mented [26, 29, 30]. For other immunosuppressive drugs,
there are mostly limited series and case reports published.
Mycophenolate and cyclosporine have been recommended,
probably also because they are used for myasthenia gravis.
Rituximab is a monoclonal antibody that speciﬁcally targets
B lymphocytes. This drug should therefore be promising
for all autoantibody-mediated disorders, including LEMS.
A positive treatment result in a few patients has recently
been reported [28, 31]. Intravenous immunoglobulin is
used for several paraneoplastic disorders, and it has a well-
proven eﬀect for acute exacerbations of myasthenia gravis
as well. A beneﬁcial short-term eﬀect has been reported
for LEMS, probably to the same degree for paraneoplastic
and no-tumour LEMS. An EFNS guideline concludes that
intravenous immunoglobulin may be tried in LEMS [32].
Plasma exchange has probably a similar eﬀect, but is less
useful as a long-term therapy [30].
Physical training can be carried out safely in mild
and moderate LEMS [26]. Overweight should be avoided.
All complicating disorders, such as respiratory infections,
should be vigorously treated. Drugs with a potential negative
impact on neuromuscular transmission should be avoided.
Standardvaccinationprogrammesarerecommendedalsofor
LEMS patients. Treatment with intravenous immunoglobu-
lin during pregnancy should be considered due to the risk
of fetal arthrogryposis, similar to what is seen in myasthenia
gravis. Transient neonatal LEMS due to transplacental
transfer of IgG antibodies has been described [33].
Eﬀective treatment for the SCLC can improve the
paraneoplastic LEMS as well. For LEMS patients with SCLC,
the anticancer treatment is crucial. Survival for patients with
SCLC and LEMS is slightly better than for SCLC patients
without LEMS [3]. However, presence of VGCC antibodies
without manifest LEMS does not seem to increase survival.
Nor is presence of SOX antibodies in paraneoplastic LEMS
linked to any increase in survival [6].
8.FuturePerspectives
For one group of LEMS patients, the cause of the disease is
known to be a SCLC. But even if LEMS represents an early
symptom of a causative tumour, the prognosis for survival
is not good. More eﬀective cancer treatment is the main
challenge for this patient group.
For the other half of LEMS patients, the cause of the
disease is unknown. However, the pathogenesis is very
well understood, and the pathogenic antibodies have been
characterized in detail. Still the therapy is immunologically
unspeciﬁc or semispeciﬁc and combined with symptomatic
treatment. Antigen-speciﬁc treatment should be an aim,
suppressing or modulating the immune response against
VGCC speciﬁcally. The rarity of LEMS hampers research.
The new and more selective immunoactive drugs already on
themarketandwithaproveneﬀectforlesswellcharacterized
disorders, have not been tried in controlled studies for
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